🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
Phase 1 will evaluate the safety and tolerability at different dose levels ...
Status
Recruiting
Location
Children's Hospital Los Angeles
Start Date
2020-03-12
Trial ID
NCT04094610
Treatments Being Tested
The purpose of this study is to evaluate the efficacy and safety of repotre...
Status
Active Not Recruiting
Location
Local Institution - 0221
Start Date
2023-12-21
Trial ID
NCT06140836
Treatments Being Tested
The purpose of the study if to evaluate the effect of Repotrectinib on the ...
Status
Completed
Location
Local Institution - 0001
Start Date
2025-12-31
Trial ID
NCT07223671
Treatments Being Tested
Phase 1 dose escalation will determine the first cycle dose-limiting toxici...
Status
Recruiting
Location
Local Institution - 2129
Start Date
2017-03-07
Trial ID
NCT03093116
Treatments Being Tested
To find out if the combination of repotrectinib and fulvestrant can control...
Status
Terminated
Location
MD Anderson Cancer Center
Start Date
2024-08-08
Trial ID
NCT06408168
Treatments Being Tested
This is a Phase 1 study to evaluate the potential drug-drug interaction (DD...
Status
Withdrawn
Location
Gabrail Cancer Research Center
Start Date
2024-11-15
Trial ID
NCT05828303
Treatments Being Tested
This study will collect safety information during routine medical care for ...
Status
Recruiting
Location
CMIC Co., Ltd.
Start Date
2025-11-20
Trial ID
NCT07755826
Treatments Being Tested
A Phase 1b/2 Study of Repotrectinib in Combination with Other Anticancer Th...
Status
Terminated
Location
Local Institution - 2101
Start Date
2021-09-23
Trial ID
NCT05071183
Treatments Being Tested
REPOSE is a phase II clinical trial exploring the safety and efficacy of re...
Status
Recruiting
Location
Medizinische Universität Graz
Start Date
2025-06-27
Trial ID
NCT06315010
Treatments Being Tested
ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but ...
Status
Recruiting
Location
CH Aix-en-Provence
Start Date
2024-10-01
Trial ID
NCT06552234
Treatments Being Tested